地塞米松植入剂治疗葡萄膜炎的真实世界疗效与安全性
这项多中心回顾性观察研究纳入152眼、共358次地塞米松植入剂注射,评估其治疗葡萄膜炎的真实疗效与安全性。随访平均19.0个月,最佳矫正视力平均提升12.1个字母,81.4%的玻璃体炎消退,但28.3%出现眼压升高、40.2%的无晶状体眼需白内障手术。研究认为该植入剂对非感染性葡萄膜炎有效且安全,并发症可管理。
要点
- 地塞米松植入剂使最佳矫正视力平均提升12.1个字母,64.5%患眼提升≥5个字母。
- 81.4%的玻璃体炎达到玻璃体混浊评分0+,59.7%的基线黄斑水肿眼解剖应答。
- 眼压升高发生率为28.3%,无需滤过手术或激光治疗;40.2%的无晶状体眼平均11.2个月后行白内障手术。
核心结论
- 地塞米松植入剂对非感染性葡萄膜炎具有疗效和安全性,白内障和眼压升高并不少见但易于管理。
研究设计与样本
- 多中心回顾性观察研究,纳入152眼,仅接受358次地塞米松植入剂注射,平均随访19.0个月。
主要发现
- 治疗指征为黄斑水肿(51.3%)、玻璃体炎伴黄斑水肿(40.1%)、玻璃体炎(5.3%)及其他原因(3.3%)。
- 随访期间最佳矫正视力平均提升12.1个字母,提升≥5、≥10、≥15个字母的比例分别为64.5%、50.7%、35.5%。
- 基线有黄斑水肿的眼中59.7%为解剖应答者,81.4%的玻璃体炎消退(玻璃体混浊评分=0+)。
- 眼压升高(眼压≥25 mmHg和/或较基线升高≥10 mmHg)发生于28.3%的患者,无需滤过手术或激光治疗。
- 40.2%的无晶状体眼在首次注射后平均11.2个月行白内障手术。
关键数值与推荐
- 最佳矫正视力提升≥5、≥10、≥15个字母的比例分别为64.5%、50.7%、35.5%。
- 黄斑水肿解剖应答率为59.7%,玻璃体炎消退(玻璃体混浊评分=0+)率为81.4%。
- 眼压升高定义为眼压≥25 mmHg和/或较基线升高≥10 mmHg,发生率为28.3%。
- 无晶状体眼白内障手术率为40.2%,平均在首次注射后11.2个月进行。
临床怎么用
- 地塞米松植入剂可用于非感染性葡萄膜炎伴黄斑水肿或玻璃体炎,需监测眼压和白内障进展。
- 眼压升高和白内障术后并发症可管理,无需滤过手术或激光治疗。
局限性
- 回顾性观察设计可能引入选择偏倚和信息偏倚。
- 缺乏对照组,无法与其它治疗直接比较。
- 平均随访19.0个月,长期安全性数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the real-life efficacy and safety of the intravitreal dexamethasone implant in uveitis. METHODS: This retrospective observational multicentric study included 152 eyes treated exclusively by 358 dexamethasone implant injections. The main outcome measures included change in the best-corrected visual acuity, central macular thickness, and vitreous haze score. RESULTS: Patients were treated with dexamethasone implant for macular edema (51.3%), vitritis with macular edema (40.1%), vitritis (5.3%), and other causes (3.3%). The mean duration of follow-up was 19.0 months. The mean gain in best-corrected visual acuity during follow-up was +12.1 letters. An improvement in best-corrected visual acuity ≥5, 10, and 15 letters was found in 64.5, 50.7, and 35.5% of cases, respectively. 59.7% of eyes with macular edema at baseline were found to be anatomical responders. Vitritis resolution (vitreous haze = 0+) was obtained in 81.4% of cases. Ocular hypertension (intraocular pressure ≥25 mmHg and/or gain ≥10 mmHg from baseline) occurred in 28.3% of patients. No filtering surgery/laser therapy was required. A total of 40.2% of phakic subjects underwent cataract surgery on average 11.2 months after the first injection. CONCLUSION: This study confirms the efficacy and safety of the dexamethasone implant in noninfectious uveitis. Cataract and ocular hypertension were not uncommon but easily manageable.
引用
- Mathis T, Cerquaglia A, Weber M, et al. UVEITIS TREATED WITH DEXAMETHASONE IMPLANT. Retina. 2021. PMID: 32618834. doi:10.1097/IAE.0000000000002901
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。